Publication:
Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress.

Loading...
Thumbnail Image

Date

2022-03-17

Authors

Torrente-Lopez, Anabel
Hermosilla, Jesus
Salmeron-Garcia, Antonio
Cabeza, Jose
Navas, Natalia

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

MDPI AG
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Nivolumab, formulated in the medicine Opdivo® (10 mg/mL), is a therapeutic monoclonal antibody (mAb) used in the treatment of different types of cancer. Currently, there is insufficient knowledge about the behaviour of this protein with regards to the risk associated with its routine handling or unintentional mishandling, or when subjected to stress conditions in hospitals. These conditions can be simulated in forced degradation studies, which provide an in-depth understanding of the biophysical and biochemical properties of mAbs. In this study, we carried out a physicochemical and functional characterisation of nivolumab, which was subjected to various stress conditions: heat, freeze/thaw cycles, agitation, light exposure and high hypertonic solution. We used a wide range of analytical techniques: Far-UV CD, IT-FS, DLS, SE/UHPLC(UV)-[Native]MS, and ELISA. The results show that exposure to light was the stress test with the greatest impact on the samples, revelling the formation of non-natural dimers and a different isoform profile. In addition, nivolumab (Opdivo®) demonstrated stability up to 60 °C (1 h). As regards functionality all the nivolumab (Opdivo®) stressed samples were found to be stable except for those subjected to light and agitation, and to a lesser extent, those subjected to FTC 5 and NaCl stresses.

Description

MeSH Terms

Nivolumab
Antibodies, Monoclonal
Sodium Chloride
Chromatography, High Pressure Liquid
Exercise Test
Neoplasms
Protein Isoforms
Enzyme-Linked Immunosorbent Assay
Hospitals

DeCS Terms

Anticuerpos monoclonales
Cloruro de sodio
Cromatografía líquida de alta presión
Ensayo de inmunoadsorción enzimática
Hospitales
Isoformas de proteínas
Neoplasias
Nivolumab
Prueba de esfuerzo

CIE Terms

Keywords

UHPLC-MS, comprehensive analytical characterisation, forced degradation, isoform profile, nivolumab

Citation

Torrente-López A, Hermosilla J, Salmerón-García A, Cabeza J, Navas N. Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress. Pharmaceutics. 2022 Mar 23;14(4):692